Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 131

James, A. E. and J. D. Driskell (2013) Monitoring gold nanoparticle conjugation and analysis
of biomolecular binding with nanoparticle tracking analysis (NTA) and dynamic light
scattering (DLS). Analyst 138 (4):1212-1218.
Jung, T., W. Kamm, A. Breitenbach, K. D. Hungerer, E. Hundt, and T. Kissel (2001) Tetanus
toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-
co-glycolide): Evaluation of antibody response after oral and nasal application in mice.
Pharm Res 18 (3):352-360.
Keck, C. M. and R. H. Muller (2013) Nanotoxicological classification system (NCS)—a guide
for the risk-benefit assessment of nanoparticulate drug delivery systems. Eur J Pharm
Biopharm 84 (3):445-448.
Labouta, H. I., L. K. el-Khordagui, T. Kraus, and M. Schneider (2011) Mechanism and deter-
minants of nanoparticle penetration through human skin. Nanoscale 3 (12):4989-4999.
Labouta, H. I. and M. Schneider (2013) Interaction of inorganic nanoparticles with the skin
barrier: Current status and critical review. Nanomedicine 9 (1):39-54.
Lademann, J., H. Richter, A. Teichmann, N. Otberg, U. Blume-Peytavi, J. Luengo, B. Weiss,
U. F. Schaefer, C. M. Lehr, R. Wepf, and W. Sterry (2007) Nanoparticles—An efficient
carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 66 (2):159-164.
Lampen, A., Y. Zhang, I. Hackbarth, L. Z. Benet, K. F. Sewing, and U. Christians (1998)
Metabolism and transport of the macrolide immunosuppressant sirolimus in the small
intestine. J Pharmacol Exp Ther 285 (3):1104-1112.
Lamprecht, A., U. Schafer, and C. M. Lehr (2001) Size-dependent bioadhesion of micro-
and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceut Res 18
(6):788-793.
Landsiedel, R., E. Fabian, L. Ma-Hock, B. van Ravenzwaay, W. Wohlleben, K. Wiench, and
F. Oesch (2012) Toxico-/biokinetics of nanomaterials. Arch Toxicol 86 (7):1021-1060.
Lasic, D. (1995) The “Stealth” Liposome: A Prototypical Biomaterial. Chem Rev 95
(8):2601-2628.
Lasic, D. D. (1996) Doxorubicin in sterically stabilized liposomes. Nature 380 (6574):561-562.
Liversidge, G. G. and K. C. Cundy (1995) Particle size reduction for improvement of oral
bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline
danazol in beagle dogs. Int J Pharm 125 (1):91-97.
Liversidge, G. G., K. C. Cundy, J. F. Bishop, and D. A. Czekai (1992) Surface modified drug
nanoparticles. US-Patent 5145684, Issued on September 8, 1992.
Mathew, T. H., C. Van Buren, B. D. Kahan, K. Butt, S. Hariharan, and J. J. Zimmerman (2006)
A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute
renal allograft rejection. J Clin Pharmacol 46 (1):76-87.
Matsumura, Y. and H. Maeda (1986) A new concept for macromolecular therapeutics in cancer
chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor
agent smancs. Cancer Res 46:6387-6392.
McNeil, S. E (2009) Nanoparticle therapeutics: A personal perspective. Wiley Interdiscip Rev
Nanomed Nanobiotechnol 1 (3):264-271.
McNeish, J (2004) Embryonic stem cells in drug discovery. Nat Rev Drug Discov 3 (1):70-80.
Merisko-Liversidge, E., G. G. Liversidge, and E. R. Cooper (2003) Nanosizing: A formulation
approach for poorly-water-soluble compounds. Eur J Pharm Sci 18 (2):113-120.
Miele, E., G. P. Spinelli, E. Miele, F. Tomao, and S. Tomao (2009) Albumin-bound formulation
of paclitaxel (Abraxane ® ABI-007) in the treatment of breast cancer. Int J Nanomedicine
4 (4):99-105.
Mittal, A., A. S. Raber, and S. Hansen (2013) Particle based vaccine formulations for transcu-
taneous immunization. Hum Vaccin Immunother 9 (9):1950-1955.
Mittal, A., A. S. Raber, U. F. Schaefer, S. Weissmann, T. Ebensen, K. Schulze, C. A. Guzman,
C. M. Lehr, and S. Hansen (2013) Non-invasive delivery of nanoparticles to hair fol-
licles: A perspective for transcutaneous immunization. Vaccine 31 (34):3442-3451.